· Introduces innovative Gastrointestinal
portfolio for patients with Inflammatory Bowel Diseases (IBD) and
Ulcerative Colitis and Crohn's Disease
· Kynteles®
is likely to benefit patients with a low risk of serious or opportunistic
infections like Tuberculosis
· Current disease
burden for IBD is over 1.5 million in India
Takeda
India, part of the Takeda Pharmaceutical Company Limited, a global values-based
R&D-driven biopharmaceutical leader, today announced the expansion
of its highly innovative portfolio for patients in the country with the launch
of Kynteles® (generic name: Vedolizumab) as part of its Gastrointestinal (GI)
portfolio. GI is Takeda's second therapeutic area in India after Rare Diseases
(Haematology, Genetic Diseases, and Immunology).
Kynteles® is used for the
treatment of adult patients with moderate
to severely active Ulcerative Colitis (UC) and Crohn's Disease
(CD). Kynteles®, more widely
known as Entvyio®, has shown favourable safety and efficacy results in treating
patients suffering from moderate to severe IBD.
Speaking about the
launch, Koki Sato, Country Head, Takeda India , said, "At
Takeda, we are continuously working towards developing innovative medicines to
considerably improve the quality of life of patients. The launch of our highly
innovative GI portfolio is a testimony of our commitment to India and
patients living with diseases like UC and CD. Patient access to Kynteles® will
further augment our vision of providing additional and innovative treatment
options to HCPs treating UC and CD."
Both UC and CD are chronic
idiopathic Inflammatory Bowel Diseases that can be debilitating and sometimes
lead to life-threatening complications and require life-long disease
management. Therefore, their treatments involve ensuring long-term remission
with a proven safety profile. Entyvio® is currently marketed in more than 60 countries.
In just five years since its global launch, Entyvio® has touched over 415,000
cumulative patient-years of experience.
There are currently over 1.5 million IBD patients in India .
New Delhi, INDIA, July 08, 2020